Thumbnail Image
Publication

Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial.

Paoletti, C
; 
Schiavon, G
; 
Dolce, E
; 
Darga, E
; 
Carr, T
; 
Geradts, J
; 
Hoch, M
; 
Klinowska, T
; 
Lindemann, J
; 
Marshall, G
... show 10 more
Citations
Altmetric:
Abstract
Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERDs). During the first-in-human study of oral SERD AZD9496, early changes in circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) were explored as potential non-invasive tools, alongside paired tumor biopsies, to assess pharmacodynamics and early efficacy.
Authors
Paoletti, C
Schiavon, G
Dolce, E
Darga, E
Carr, T
Geradts, J
Hoch, M
Klinowska, T
Lindemann, J
Marshall, G
Morgan, S
Patel, P
Rowlands, V
Sathiyayogan, N
Aung, K
Hamilton, E
Patel, M
Armstrong, Anne C
Jhaveri, K
Im, S
Iqbal, Nadia
Butt, Fouziah
Dive, Caroline
Harrington, E
Barrett, J
Baird,
Hayes, D
Affiliation
Internal Medicine- Div. of Hematology/Oncology, University of Michigan Rogel Cancer Center (UM CCC)
Description
Date
2018-08-06
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
From UNPAYWALL
Adobe PDF, 1.56 MB
Keywords
Type
Article
Citation
Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial. 2018, Clin Cancer Res
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621261
Embedded videos